Literature DB >> 21680575

Different annual recurrence pattern between lumpectomy and mastectomy: implication for breast cancer surveillance after breast-conserving surgery.

Ke-Da Yu1, Shuang Li, Zhi-Ming Shao.   

Abstract

PURPOSE: To investigate the recurrence pattern and annual recurrence risk after breast-conserving surgery and compare them with those after mastectomy.
METHODS: This retrospective analysis included 6,135 consecutive unilateral breast cancer patients undergoing surgery in 1998-2008, with 847 lumpectomy patients and 5,288 mastectomy patients. Recurrence patterns were scrutinized and annual recurrence rates were calculated. Furthermore, a literature-based review including seven relevant studies was subsequently performed to confirm our single-institution data-based observations.
RESULTS: After lumpectomy, 50.9% of recurrences occurred within 3 years and 30.2% of recurrences were detected at 3-5 years; after mastectomy, 64.9% of recurrences occurred within 3 years and 20.4% occurred at 3-5 years. The major locoregional recurrence pattern after lumpectomy was ipsilateral breast tumor recurrence, which mainly (81.3%) occurred ≤5 years postsurgery but with a low incidence of 37.5% ≤3 years postsurgery. Annual recurrence curves indicated that the relapse peak after mastectomy emerged in the first 2 years; however, recurrence after lumpectomy increased annually with the highest peak near 5 years. By reviewing relevant studies, we confirmed our finding of different annual recurrence patterns for lumpectomy and mastectomy patients. The hazard ratio of dying for those recurring ≤5 years postlumpectomy relative to patients relapsing >5 years postlumpectomy was 4.62 (95% confidence interval, 1.05-20.28; p = .042).
CONCLUSIONS: Different recurrence patterns between mastectomy and lumpectomy patients imply that scheduling of surveillance visits should be more frequent during the 4-6 years after lumpectomy. Further prospective trials addressing the necessity of frequent and longer surveillance after lumpectomy are warranted.

Entities:  

Mesh:

Year:  2011        PMID: 21680575      PMCID: PMC3228157          DOI: 10.1634/theoncologist.2010-0366

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  37 in total

1.  Survival and pattern of failure following locoregional recurrence of breast cancer.

Authors:  C Kamby; L Sengeløv
Journal:  Clin Oncol (R Coll Radiol)       Date:  1999       Impact factor: 4.126

2.  Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.

Authors:  Bernard Fisher; Jong-Hyeon Jeong; Stewart Anderson; John Bryant; Edwin R Fisher; Norman Wolmark
Journal:  N Engl J Med       Date:  2002-08-22       Impact factor: 91.245

3.  The prognostic significance of late local recurrence after breast-conserving therapy.

Authors:  J M Kurtz; J M Spitalier; R Amalric; H Brandone; Y Ayme; J Jacquemier; D Hans; C Bressac
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-01       Impact factor: 7.038

4.  Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute.

Authors:  A S Lichter; M E Lippman; D N Danforth; T d'Angelo; S M Steinberg; E deMoss; H D MacDonald; C M Reichert; M Merino; S M Swain
Journal:  J Clin Oncol       Date:  1992-06       Impact factor: 44.544

5.  Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials.

Authors:  A C Voogd; M Nielsen; J L Peterse; M Blichert-Toft; H Bartelink; M Overgaard; G van Tienhoven; K W Andersen; R J Sylvester; J A van Dongen
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

6.  Ipsilateral breast tumor recurrence postlumpectomy is predictive of subsequent mortality: results from a randomized trial. Investigators of the Ontario Clinical Oncology Group.

Authors:  T Whelan; R Clark; R Roberts; M Levine; G Foster
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-08-30       Impact factor: 7.038

Review 7.  Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: a meta-analysis and systematic review.

Authors:  G H de Bock; J Bonnema; J van der Hage; J Kievit; C J H van de Velde
Journal:  J Clin Oncol       Date:  2004-10-01       Impact factor: 44.544

8.  Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up.

Authors:  M Rosselli Del Turco; D Palli; A Cariddi; S Ciatto; P Pacini; V Distante
Journal:  JAMA       Date:  1994-05-25       Impact factor: 56.272

9.  Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer.

Authors:  Umberto Veronesi; Natale Cascinelli; Luigi Mariani; Marco Greco; Roberto Saccozzi; Alberto Luini; Marisel Aguilar; Ettore Marubini
Journal:  N Engl J Med       Date:  2002-10-17       Impact factor: 91.245

10.  Early detection of recurrences in the follow-up of primary breast cancer in an asymptomatic or symptomatic phase.

Authors:  Maria Antonietta Perrone; Antonino Musolino; Maria Michiara; Beatrice Di Blasio; Mariangela Bella; Vittorio Franciosi; Giorgio Cocconi; Roberta Camisa; Renata Todeschini; Stefano Cascinu
Journal:  Tumori       Date:  2004 May-Jun
View more
  9 in total

1.  Trends and present treatment patterns of early breast cancer in Southwest China.

Authors:  Qiancheng Hu; Ting Luo; Ping He; Xiaorong Zhong; Tinglun Tian; Qing Lv; Xi Yan; Hong Zheng
Journal:  Pathol Oncol Res       Date:  2014-08-06       Impact factor: 3.201

2.  Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer.

Authors:  Ke-Da Yu; Rui Zhu; Ming Zhan; Angel A Rodriguez; Wei Yang; Stephen Wong; Andreas Makris; Brian D Lehmann; Xi Chen; Ingrid Mayer; Jennifer A Pietenpol; Zhi-Ming Shao; W Fraser Symmans; Jenny C Chang
Journal:  Clin Cancer Res       Date:  2013-04-02       Impact factor: 12.531

3.  The effect of delayed adjuvant chemotherapy on relapse of triple-negative breast cancer.

Authors:  Shuang Li; Ding Ma; Hao-Hong Shi; Ke-Da Yu; Qiang Zhang
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 4.  A new hypothesis for the cancer mechanism.

Authors:  Xiaolong Meng; Jie Zhong; Shuying Liu; Mollianne Murray; Ana M Gonzalez-Angulo
Journal:  Cancer Metastasis Rev       Date:  2012-06       Impact factor: 9.264

5.  Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom.

Authors:  Anil Vaidya; Param Vaidya; Brigitte Both; Chris Brew-Graves; Max Bulsara; Jayant S Vaidya
Journal:  BMJ Open       Date:  2017-08-17       Impact factor: 2.692

6.  Risk factors of locoregional relapse in locally advanced breast cancer treated with neoadjuvant chemotherapy following mastectomy and radiotherapy.

Authors:  Liang Huang; Sheng Chen; Wentao T Yang; Zhiming Shao
Journal:  Oncotarget       Date:  2017-06-13

7.  2-(fluorine-18)-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography after breast conserving surgery: Correlation with molecular markers of breast cancer.

Authors:  Salih Ozguven; Sabahat Inanir; Halil Turgut Turoglu; Tanju Yusuf Erdil; Mustafa Umit Ugurlu; Bahadir Gulluoglu
Journal:  Indian J Nucl Med       Date:  2016 Jul-Sep

8.  Influence of delayed initiation of adjuvant chemotherapy on breast cancer survival is subtype-dependent.

Authors:  Ke-Da Yu; Lei Fan; Li-Xin Qiu; Hong Ling; Yi-Zhou Jiang; Zhi-Ming Shao
Journal:  Oncotarget       Date:  2017-07-11

9.  HER2 overexpression in ductal carcinoma in situ is associated with ipsilateral breast cancer recurrence after conservative surgery.

Authors:  Di-He Gong; Jin-Yu Ge; Yi-Yu Chen; Ke-Feng Ding; Ke-Da Yu
Journal:  Transl Cancer Res       Date:  2020-06       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.